Clinical effect of Bretschneider-HTK and St. Thomas cardioplegia on hemodynamic performance after bypass measured using an automatic datalogging database system. 1988

R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
Dept. of Anesthesia, University Hospital Groningen, Netherlands.

A prospective consecutive study was undertaken to compare the hemodynamic effect of two cardioplegic solutions in CABG patients after bypass, and in relation to aorta occlusion time with the support of a automatic datalogging database. A total of 249 patients were randomized. One group received Bretschneider cardioplegic HTK solution (132 patients, group I) the other group received St. Thomas cardioplegic solution (117 patients, group II). The data was divided in four periods of aortic clamp time: less than or equal to 40 min (group I 26 patients, group II 32 patients); 41-60 min (group I 49 patients, group II 47 patients); 61-80 min (group I 30 patients, group II 29 patients); and greater than 80 minutes (group I 27 pts, group II 9 patients). Anesthesia regime and therapeutic drugs and infusions were given in both groups in similar dosages. Within both groups HR, CO, PAP, PCWP increased after bypass in relation to prebypass values. SVR decreased in both groups by 30%, MAP and PVR decreased only in group I. Between group I and II differences were found in the CI (3.0 vs. 3.3 l/min/m2), MAP (70 vs. 76 mmHg), PMAR (18 vs. 16 mHg), and SVR (827 vs. 954 dyn.sec.cm-5). In significantly more of the patients in group I, sinus rhythm started spontaneously after the release of the aorta clamp (39.5% vs. 20.4%, p less than 0.005). Patients in group I needed temporarily a pacemaker after bypass in 6.3% cases (in 1.1% of patients in group II,). There was no relation of the hemodynamic data in relation to aorta occlusion time within the groups.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008353 Mannitol A diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity. (L)-Mannitol,Osmitrol,Osmofundin
D011189 Potassium Chloride A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA. Slow-K,Chloride, Potassium
D011343 Procaine A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Anuject,Geriocaine,Gerokit,Hewedolor-Procain,Lophakomp-Procain N,Novocain,Novocaine,Procain Braun,Procain Jenapharm,Procain Rödler,Procain Steigerwald,Procain curasan,Procaina Serra,Procaine Hydrochloride,Pröcaine chlorhydrate Lavoisier,Röwo Procain,procain-loges,Hydrochloride, Procaine
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002122 Calcium Chloride A salt used to replenish calcium levels, as an acid-producing diuretic, and as an antidote for magnesium poisoning. Calcium Chloride Dihydrate,Calcium Chloride, Anhydrous
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003201 Computers Programmable electronic devices designed to accept data, perform prescribed mathematical and logical operations at high speed, and display the results of these operations. Calculators, Programmable,Computer Hardware,Computers, Digital,Hardware, Computer,Calculator, Programmable,Computer,Computer, Digital,Digital Computer,Digital Computers,Programmable Calculator,Programmable Calculators
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose

Related Publications

R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
December 1990, The Thoracic and cardiovascular surgeon,
R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
January 2024, The Thoracic and cardiovascular surgeon,
R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
December 2019, The Journal of thoracic and cardiovascular surgery,
R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
April 1990, Journal of anesthesia,
R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
June 2023, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia,
R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
May 1990, Kyobu geka. The Japanese journal of thoracic surgery,
R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
January 2019, Mediators of inflammation,
R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
February 2022, Medicina (Kaunas, Lithuania),
R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
January 2022, Annals of cardiac anaesthesia,
R C Gallandat Huet, and G F Karliczek, and J N van der Heide, and U Brenken, and B Mooi, and J J van der Broeke, and I Jenkins, and A F de Geus
June 2023, Perfusion,
Copied contents to your clipboard!